LAKESHORE BIOPHARMA CO LTD (LSB) Stock Price & Overview

NASDAQ:LSB • KYG9845F2080

Current stock price

0.627 USD
-0.16 (-20.68%)
At close:
0.5399 USD
-0.09 (-13.89%)
After Hours:

The current stock price of LSB is 0.627 USD. Today LSB is down by -20.68%. In the past month the price decreased by -25%. In the past year, price decreased by -18.57%.

LSB Key Statistics

52-Week Range0.5743 - 5.7
Current LSB stock price positioned within its 52-week range.
1-Month Range0.5743 - 0.8799
Current LSB stock price positioned within its 1-month range.
Market Cap
25.839M
P/E
N/A
Fwd P/E
4.39
EPS (TTM)
-0.73
Dividend Yield
N/A

LSB Stock Performance

Today
-20.68%
1 Week
-24.50%
1 Month
-25.00%
3 Months
-36.02%
Longer-term
6 Months -77.36%
1 Year -18.57%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

LSB Stock Chart

LAKESHORE BIOPHARMA CO LTD / LSB Daily stock chart

LSB Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to LSB. When comparing the yearly performance of all stocks, LSB is a bad performer in the overall market: 92.39% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LSB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LSB. LSB has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LSB Earnings

Next Earnings DateDec 15, 2025
Last Earnings DateJul 31, 2025
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 4.58%

LSB Forecast & Estimates

5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.

For the next year, analysts expect an EPS growth of 105.67% and a revenue growth 75.61% for LSB


Analysts
Analysts80
Price Target31.62 (4943.06%)
EPS Next Y105.67%
Revenue Next Year75.61%

LSB Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

LSB Financial Highlights

Over the last trailing twelve months LSB reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 87.13% compared to the year before.


Income Statements
Revenue(TTM)614.96M
Net Income(TTM)-99.98M
Industry RankSector Rank
PM (TTM) N/A
ROA -7.31%
ROE -20.01%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%70.82%
Sales Q2Q%79.55%
EPS 1Y (TTM)87.13%
Revenue 1Y (TTM)7.24%

LSB Ownership

Ownership
Inst Owners0.66%
Shares41.21M
Float5.08M
Ins Owners12.67%
Short Float %N/A
Short RatioN/A

About LSB

Company Profile

LSB logo image LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Company Info

IPO: 2021-07-30

LAKESHORE BIOPHARMA CO LTD

Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District

Beijing BEIJING CN

Employees: 573

LSB Company Website

LSB Investor Relations

Phone: 17327133678

LAKESHORE BIOPHARMA CO LTD / LSB FAQ

Can you describe the business of LAKESHORE BIOPHARMA CO LTD?

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.


Can you provide the latest stock price for LAKESHORE BIOPHARMA CO LTD?

The current stock price of LSB is 0.627 USD. The price decreased by -20.68% in the last trading session.


Does LSB stock pay dividends?

LSB does not pay a dividend.


How is the ChartMill rating for LAKESHORE BIOPHARMA CO LTD?

LSB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the PE ratio for LSB stock?

LAKESHORE BIOPHARMA CO LTD (LSB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).